Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
homoharringtonine/злокачественная опухоль
Ссылка сохраняется в буфер обмена
Страница 1 от 74 полученные результаты
Homoharringtonine: an effective new natural product in cancer chemotherapy.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Homoharringtonine (HHT) is a cytotoxic alkaloid isolated from the evergreen tree cephalotaxus harringtonia native to the southern provinces of China. The principal mechanism of action of HHT is the inhibition of protein synthesis in a dose- and time-dependent manner by acting on the ribosomes of
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Homoharringtonine (HHT) is an ester of cephalotaxine (CET), both of which derive from the Chinese coniferous tree Cephalotaxus hainanensis. HHT inhibited tumor cell growth at molar ranges comparable to established cytostatic drugs, whereas CET was 3-4 orders of magnitude less active. Inhibition
Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Overexpressed EphB4 conduce to tumor development and is regarded as a potential anticancer target. Homoharringtonine (HHT) has been approved for hematologic malignancies treatment, but its effect on hepatocellular carcinoma (HCC) has not been studied. This study elucidated HHT could restrain the
Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Harringtonine and its derivative homoharringtonine are ester-containing anti-leukemic alkaloids isolated from the tree Cephalotaxus harringtonia. In order to compare their antitumor activity against solid tumors, in vitro culture of fresh tumor cells from 23 patients was carried out with a soft agar
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
One hallmark of cancer cells is their ability to evade physiologic signals causing regulated cell death (RCD). Correspondingly, TRAIL-based therapies to eliminate human cancer cells via enforced induction of apoptosis have been established and represent a promising approach in anti-cancer
Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Advanced subcutaneous Colon 38 tumours in mice were used for the assessment of activity of a number of anticancer drugs. Activity was measured by histological examination of tumours 24 h after a single dose of the drug and in some cases by tumour growth delay. Agents thought to exert their cytotoxic
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Tyrosine kinase inhibitors (TKIs) are mostly used in non-small cell lung cancer (NSCLC) treatment. Unfortunately, treatment with Gefitinib for a period of time will result in drug resistance and cause treatment failure in clinic. Therefore, exploring novel compounds to overcome this resistance is
Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Triple negative breast cancers (TNBC) without BRCA1/2 gene mutation or BRCAness are nowadays the breast malignancies most difficult to treat. Improvement of their treatment, for all phases of the disease, is an important unmet medical need. We analyzed the effect of homoharringtonine (HHT), a
Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Homoharringtonine (HHT), an inhibitor of protein synthesis, has been used to treat leukemia. Its therapeutic effects on non-small cell lung adenocarcinoma carrying KRAS mutation and their immune system are less understood. The present study examined the therapeutic efficacy and the immune effects of
A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Twenty-four previously untreated, ambulatory patients with advanced colorectal carcinoma were treated with either caracemide (11 patients) or homoharringtonine (13 patients). No objective responses were observed in any of the treatment cohorts. Caracemide was well tolerated with the exception of one
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and
Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
A phase II trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m2/day by continuous 5 day intravenous infusion (3 mg/m2/day x 5 days for heavily pretreated patients). Courses were repeated
Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Homoharringtonine, a plant alkaloid, has been reported to suppress protein synthesis and approved by U.S. Food and Drug Administration for chronic myeloid leukemia treatment. Here we show that homoharringtonine also potently inhibits cell growth/viability and induces cell cycle arrest and apoptosis
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Renal cell carcinoma (RCC) accounts for 85% of primary renal neoplasms, and is rarely curable when metastatic. Approximately 70% of RCCs are clear-cell type (ccRCC), and in >80% the von Hippel-Lindau (VHL) gene is mutated or silenced. We developed a novel, high-content, screening strategy for the
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The purpose of this study was to review the progress in clinical and translational research in chronic myelogenous leukemia (CML) over the past 20 years at M.D. Anderson Cancer Center. The CML database updating the clinical and basic research investigations was reviewed as the source of this report.
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
